Registry Protocol
Participation is open for all physicians worldwide with expertise on hepatitis delta treatment.
Patients with chronic hepatitis delta will be screened regardless of HDV or HBV genotype. Prospective and retrospective inclusion of patients is possible. There will be no limit in the number of patients recruited.
The primary objectives are:
- To characterize the morbidity and mortality of hepatitis delta patients
- To characterize the impact of therapy on the morbidity and mortality of hepatitis delta patients
Inclusion criteria of the patient registry:
- Positive HBs antigen and anti HDV for longer than 6 months.
- HDV RNA positive
- Signed informed consent or ethical approval of retrospective data entry
- Absence of any cause of relevant liver disease other than HDV (i.e. hemochromatosis, autoimmune hepatitis, alcoholic or toxic liver disease, etc.)
Documentation in the Hepatitis Delta International Registry is now closed. If you are interested in data analysis or further collaborations concerning hepatitis delta, please contact us.